Abstract:
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIB-i, IV and IVA have the structure: wherein R1, R2, R3, R4; and X, X4, X5, X7, X9; Y, Z and n are as described in the specification.
Abstract:
Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formula IIIB have the structure: wherein R1, R2, R, Ar and n are as described in the specification.
Abstract:
Compounds having kappa opioid agonist activity, compositions containing them and methods of using them as analgesics and anti-pruritic agents are provided. The compounds of formula IV have the structure: wherein X9; R1, R2, R3, R4; and n are as described in the specification.
Abstract translation:提供了具有κ阿片样物质激动剂活性的化合物,含有它们的组合物和使用它们作为止痛剂和抗瘙痒剂的方法。式IV化合物具有以下结构:其中X 9; R 1,R 2,R 3,R 4; andn如说明书中所述。
Abstract:
Anti-pruritic pharmaceutical formulations containing kappa agonist compounds and methods of prevention or treatment of pruritus in a mammal with the anti-pruritic formulations.
Abstract:
Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo�3,4-b!quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.
Abstract:
Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.
Abstract:
1-Hetero substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.
Abstract:
Compounds of the formula ##STR1## wherein Alk is lower-alkylene;R.sub.1 is hydrogen, lower-alkyl, Ar or ArCOO;R.sub.2 is hydrogen or lower-alkyl;R.sub.3 and R.sub.4 are the same or different hydrogen, fluoro, chloro, bromo, hydroxy, lower-alkoxy, lower-alkyl, or trifluoromethyl;Ar is phenyl, naphthyl, anthryl, 2-phenylethenyl or a 5- or 6-membered monocyclic or 9- or 10-membered bicyclic fused aromatic heterocyclic ring containing carbon and one or two heteroatoms independently selected from oxygen, nitrogen and sulfur, or such carbocyclic or heterocyclic rings substituted with from 1 to about 3 of lower-alkoxy, lower-alkyl, lower-alkylthio, lower-alkyl sulfinyl, lower-alkyl sulfonyl, hydroxy, cyano, amino, lower-alkylamino, dilower-alkylamino or halo;or pharmaceutically acceptable acid addition salts thereof are useful as analgesics and in the treatment of glaucoma.
Abstract:
N-[(disubstituted amino)alkyl]-3,4 or 5-aryl-1H-pyrazole-1-acetamides, useful for treating cardiac arrhythmias in mammals, are prepared by reacting a lower-alkyl ester of pyrazole-1-acetic acid with an appropriate diamine.
Abstract:
Methods and apparatus are provided for generating a garbled circuit for a client in a leakage-resilient manner, for use in secure function evaluation between the client and a server. The garbled circuit is generated by obtaining a token from the server, wherein said token comprises a leakage-protected area; querying the token gate-by-gate, wherein for each gate of said garbled circuit, the token interacts with the leakage-protected area to generate a garbled table for the gate; and receiving the garbled circuit from the token. The client can interact with the server to obtain garbled inputs; and then evaluate the garbled circuit on the garbled inputs to obtain a garbled output. A final output can be obtained by matching the garbled output with an output table in the garbled circuit.